A Phase I/Ib Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of DSM265 in Healthy Subjects and to Assess the Antimalarial Activity of DSM265 in Healthy Subjects with an Induced Blood Stage Plasmodium falciparum Infection.

Trial Profile

A Phase I/Ib Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of DSM265 in Healthy Subjects and to Assess the Antimalarial Activity of DSM265 in Healthy Subjects with an Induced Blood Stage Plasmodium falciparum Infection.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs DSM 265 (Primary)
  • Indications Malaria
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Most Recent Events

    • 06 Aug 2015 Status changed from completed to active, no longer recruiting, as reported by Australian New Zealand Clinical Trials Registry source.
    • 06 Aug 2015 Status changed from active, no longer recruiting to completed as per Australian New Zealand Clinical Trials Registry record.
    • 27 Nov 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top